These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 35872216)
21. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Greenhawt M; Abrams EM; Shaker M; Chu DK; Khan D; Akin C; Alqurashi W; Arkwright P; Baldwin JL; Ben-Shoshan M; Bernstein J; Bingemann T; Blumchen K; Byrne A; Bognanni A; Campbell D; Campbell R; Chagla Z; Chan ES; Chan J; Comberiati P; Dribin TE; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Grayson MH; Horner CC; Hourihane J; Katelaris CH; Kim H; Kelso JM; Lang D; Ledford D; Levin M; Lieberman J; Loh R; Mack D; Mazer B; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Oppenheimer J; Perrett KP; Ramsey A; Rank M; Robertson K; Sheikh J; Spergel JM; Stukus D; Tang MLK; Tracy JM; Turner PJ; Whalen-Browne A; Wallace D; Wang J; Waserman S; Witry JK; Worm M; Vander Leek TK; Golden DBK J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3546-3567. PubMed ID: 34153517 [TBL] [Abstract][Full Text] [Related]
22. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. ; MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(4):125-129. PubMed ID: 33507892 [TBL] [Abstract][Full Text] [Related]
23. COVID-19 vaccination including 198 patients with history of severe anaphylactic reaction - own observations. Wentrys Ł; Stopyra L Przegl Epidemiol; 2021; 75(3):315-325. PubMed ID: 35170287 [TBL] [Abstract][Full Text] [Related]
24. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816 [TBL] [Abstract][Full Text] [Related]
25. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. Shimabukuro T Am J Transplant; 2021 Mar; 21(3):1332-1337. PubMed ID: 33641264 [No Abstract] [Full Text] [Related]
26. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration. Desai AP; Desai AP; Loomis GJ Vaccine; 2021 Jul; 39(32):4407-4409. PubMed ID: 34215453 [TBL] [Abstract][Full Text] [Related]
27. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971 [TBL] [Abstract][Full Text] [Related]
28. Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 Vaccine Using Intradermal Skin Testing With the COVID-19 Vaccines. Shavit R; Maoz-Segal R; Offengenden I; Yahia SH; Maayan DM; Lifshitz Y; Niznik S; Deutch M; Elbaz E; Genaim H; Iancovici-Kidon M; Agmon-Levin N J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2677-2684. PubMed ID: 35973526 [TBL] [Abstract][Full Text] [Related]
30. Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site. Myles IA; Vinciguerra JS; Premus RT Vaccine; 2021 Jul; 39(32):4404-4406. PubMed ID: 34217573 [TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
32. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022. Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637 [TBL] [Abstract][Full Text] [Related]
33. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022. Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875 [TBL] [Abstract][Full Text] [Related]
34. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI). Tuyls S; Van Der Brempt X; Faber M; Gadisseur R; Dezfoulian B; Schrijvers R; Froidure A; Acta Clin Belg; 2022 Jun; 77(3):552-557. PubMed ID: 33792500 [TBL] [Abstract][Full Text] [Related]
35. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. Banerji A; Wickner PG; Saff R; Stone CA; Robinson LB; Long AA; Wolfson AR; Williams P; Khan DA; Phillips E; Blumenthal KG J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1423-1437. PubMed ID: 33388478 [TBL] [Abstract][Full Text] [Related]
36. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256 [TBL] [Abstract][Full Text] [Related]
37. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Alhumaid S; Al Mutair A; Al Alawi Z; Rabaan AA; Tirupathi R; Alomari MA; Alshakhes AS; Alshawi AM; Ahmed GY; Almusabeh HM; Alghareeb TT; Alghuwainem AA; Alsulaiman ZA; Alabdulmuhsin MA; AlBuwaidi EA; Dukhi AKB; Mufti HN; Al-Qahtani M; Dhama K; Al-Tawfiq JA; Al-Omari A Allergy Asthma Clin Immunol; 2021 Oct; 17(1):109. PubMed ID: 34656181 [TBL] [Abstract][Full Text] [Related]
38. Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders. Marković I; Božan M; Perković T; Paušek K; Nedeljković V; Perković M; Kelava T; Artuković M; Stipić Marković A Medicine (Baltimore); 2022 Jul; 101(30):e29571. PubMed ID: 35905225 [TBL] [Abstract][Full Text] [Related]
39. Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers. Ruiz-Villaverde R; Rivera-Izquierdo M; Gil-Villalba A; Pegalajar-García MD; Pérez-Rojas J; Soler-Iborte E; Valero-Ubierna MC Int J Dermatol; 2022 Oct; 61(10):1289-1293. PubMed ID: 35775137 [TBL] [Abstract][Full Text] [Related]
40. Assessment and management of allergy history with a novel mRNA vaccine. Holt C; Butler J; Sharp K; McDonald J Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 35881510 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]